0
SIGA Technologies Inc. Banner Image

SIGA Technologies Inc.

  • Ticker SIGA
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
SIGA Technologies Inc. Logo Image
  • 51-200 Employees
  • Based in New York City, New York
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks (biodefense market), vaccines and therapies for emerging infectious diseases, and health preparedness. Their lead product is TPOXX®, also known as tecovirimat and ST-246®, an orallyMore administered and intravenous (IV) formulation antiviral medicine for the treatment of human smallpox disease caused by variola virus. TPOXX is a novel small-molecule product of which 2 million oral courses have been delivered to the Strategic National Stockpile under Project BioShield. The FDA approved the oral formulation of TPOXX for the treatment of smallpox on July 13, 2018. In September 2018, SIGA signed a new contract with Biomedical Advanced Research and Development Authority (BARDA) for procurement of oral and intravenous formulations of TPOXX, and development activities.
SIGA Technologies Inc.

Most Recent Annual Report

SIGA Technologies Inc. MOST RECENT 2020 Annual Report and Form 10K

Older/Archived Annual Reports